Endoxan 1 gm/vial (IV Infusion)
1 gm vial: ৳ 982.38
Medicine Details
| Category | Details |
|---|---|
| Generic | Cyclophosphamide |
| Company | Baxter |
| Also available as |
Title
- Endoxan (Cyclophosphamide) Medicine
Categories
- Medicine
- Pharmaceuticals
- Healthcare
Description
- Effective in treating malignant lymphomas
- Also used for multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma
- Can be used in carefully selected cases of biopsy-proven 'minimal change' nephrotic syndrome in children
- Metabolized in the liver to active alkylating metabolites
- Absorbed well after oral administration with a bioavailability greater than 75%
- Elimination half-life of 3 to 12 hours
- Eliminated primarily as metabolites, with 5 to 25% excreted in urine as unchanged drug
- Low plasma protein binding of unchanged drug
- Dosage range dependent on the type of malignancy and patient's hematologic condition
- Can be administered intravenously or orally
- Leukopenic activity reportedly increased by high doses of phenobarbital
- Contraindicated in patients with severely depressed bone marrow function and previous hypersensitivity to cyclophosphamide
- Adverse effects include nausea, vomiting, anorexia, alopecia, skin rash, leukopenia, thrombocytopenia, anemia, hemorrhagic ureteritis, renal tubular necrosis, interstitial pneumonitis, and anaphylactic reactions
- Pregnancy Category D with excretion in breast milk
- Special precautions required for patients with leukopenia, thrombocytopenia, tumor cell infiltration of bone marrow, impaired hepatic function, and impaired renal function
- Similar safety profile observed in pediatric patients compared to adults
- Elderly patients may be more susceptible to toxicities
- No specific antidote for overdose, should be managed with supportive measures
- Belongs to therapeutic class of cytotoxic chemotherapy
- Requires storage at a temperature not exceeding 25°C, protected from light and moisture